Cellular And Molecular Aspects Of Mammographic Density As A Predictor Of Breast Cancer Risk In Pseudo-orthotopic Mammatrophic Environment
Funder
National Health and Medical Research Council
Funding Amount
$113,322.00
Summary
High mammographic density (MD), or denser breast tissue on mammogram, is associated with greater breast cancer risk. Despite this, the basis for its increased risk is poorly understood. This study assesses the effect of high density breast tissue transferred from high risk women at time of mastectomy into tissue engineering chambers in mice. Changes in the connective tissue harvested from the chamber were examined with specialized imaging, laboratory stains and molecular analysis.
Progesterone Regulation Of Epithelial Expansion In The Normal Human Breast
Funder
National Health and Medical Research Council
Funding Amount
$556,393.00
Summary
The ovaries play a pivotal role in breast cancer. Progesterone increases breast cancer risk, and this is likely to be a subversion of its role in the normal breast, which is to participate in the normal expansion of the epithelial cells during the menstrual cycle, but how it does this is unknown. We will explore how progesterone influences cell types in the breast similar to those that become cancerous. This will uncover potential targets for prevention and treatment.
A Novel Role For CBF? As A Regulator Of Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$682,415.00
Summary
Whole genome sequencing studies of human breast tumours identified a handful of common significantly mutated genes, all previously linked to breast cancer, except one, CBF?. Preliminary data from our lab now show that CBF? may be a new regulator of human breast cancer and metastasis. Using mice with altered CBF? levels, breast cancer models and human patient cohorts, this study aims to identify a novel role for CBF? as a new regulator of human breast cancer and potential therapeutic target.
Translating Molecular Determinants Of Susceptibility And Progression In Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$6,510,085.00
Summary
Breast cancer is the most common cancer in women. Despite improvements in prevention, detection and treatment, it is the 2nd most common cause of cancer death in Australian women. Research advances in the last decade have improved our understanding of the pathways from susceptibility to progression and metastasis but this has mostly not yet translated into better outcomes. This program aims to translate some of our fundamental discoveries to improve outcome for affected women and their families.
Clinicopathological Characterisation Of Male Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$113,322.00
Summary
Male Breast Cancer is an uncommon and poorly understood disease. Due to its low frequency, there is a paucity of studies with large numbers of patients. Our aim will be to establish one of the largest worldwide databases of Male Breast Cancer. This will allow us to more thoroughly investigate clinical, pathological and molecular characteristics of male breast cancer, improve treatment of these patients and potentially develop novel and innovative strategies for treatment of female breast cancer.
Incidence And Prognosis Of Metastatic Breast Cancer: A Population-based Data Linkage Study
Funder
National Health and Medical Research Council
Funding Amount
$97,700.00
Summary
This project will provide the first Australian population-based estimates of metastaticbreast cancer (MBC) incidence and survival in women with an initial diagnosis of early stage cancer that reflect current treatment practices. This evidence will help: women with MBC and their clinicians to make decisions about treatment and plan supportive care; researchers planning trials of MBC therapies, and future planning of cancer services.
In women there is a strong link between increased risk of breast cancer and low levels of vitamin D. We will use a novel explant system where breast tissue biopsies from women with breast cancer will be used to explore the metabolism of vitamin D and its consequences. This grant proposal will determine the dose of vitamin D that will provide a preventative strategy for breast cancer in the general population, and potential of vitamin D as an adjunct treatment in women with breast cancer.
KConFaB - A CONSORTIUM FOR RESEARCH ON FAMILIAL BREAST CANCER
Funder
National Health and Medical Research Council
Funding Amount
$1,624,711.00
Summary
Breast cancer is the most common disease of women. In families with an inherited form of breast cancer, nearly half the women in every generation can develop the disease. The aim of this Australia-wide study is to collect clinical, epidemiological and genetic data on approximately 700 of these severely-affected families. This national resource will be of great value for researchers who want to identify and characterize the genetic and life-style factors that affect the onset and progression of t ....Breast cancer is the most common disease of women. In families with an inherited form of breast cancer, nearly half the women in every generation can develop the disease. The aim of this Australia-wide study is to collect clinical, epidemiological and genetic data on approximately 700 of these severely-affected families. This national resource will be of great value for researchers who want to identify and characterize the genetic and life-style factors that affect the onset and progression of the disease. The data emerging from the study will lead to more accurate genetic counselling, better surveillance and, ultimately, better methods to prevent and treat the disease in families who inherit a predisposition to the disease.Read moreRead less
Role Of Cyclin E2 In Hormone-responsive Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$328,194.00
Summary
The female hormone estrogen stimulates the growth of breast cancers by promoting cell reproduction. We have found that cyclin E2, which is part of the machinery that controls cell reproduction, responds to estrogen. Since abnormally high levels of cyclin E2 are linked with earlier relapse in breast cancer, we wish to understand what role it plays in estrogen action and in breast cancer, how its levels are controlled, and whether too much cyclin E2 interferes with drugs that block estrogen action